Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount

Needham analyst Gil Blum has maintained their bearish stance on SRPT stock, giving a Sell rating today.

Claim 55% Off TipRanks

Gil Blum has given his Sell rating due to a combination of factors tied to Sarepta’s current performance and risk profile. Elevidys revenue slipped sequentially even as it modestly beat consensus, and management itself cautioned investors not to raise forecasts despite talking about early positive signs, highlighting lingering uncertainty around the growth trajectory.

Blum also points to elevated regulatory risk after the ESSENCE trial failed, which in his view undermines confidence in the PMO portfolio even as the company seeks broader approvals for Amondys and Vyondys. While Sarepta reaffirmed its full-year revenue guidance and holds a solid cash balance, the combination of slowing Elevidys momentum, pending safety data for broader use, and higher regulatory overhang leads him to maintain a cautious stance and keep a Sell recommendation.

In another report released today, H.C. Wainwright also reiterated a Sell rating on the stock with a $5.00 price target.